Tikcro Technologies Reports Third Quarter 2019 Results

NESS-ZIONA, Israel, Nov. 21, 2019 /PRNewswire/ -- Tikcro Technologies Ltd. TIKRF, a pre-clinical stage developer of antibodies for cancer immune-therapy, today reported its financial results for the third quarter ended September 30, 2019.

"We have concluded the pre-clinical development stage of our anti-CTLA-4 antibody, which shows strong comparative results in cancer treatment assays," said Aviv Boim, CEO of Tikcro. "At this stage, we plan to reduce operating expenses. We expect to close our lab facilities and cease pre-clinical development efforts, which incurred $546,000 of R&D expenses in the previous twelve-month period. Due to the significant costs associated with production and clinical trials as well as the evolution of the immune therapy antibody market, we will continue to explore strategic opportunities for this antibody program and other alternatives."

Financial Results for the Third Quarter Ended September 30, 2019

Net loss for the third quarter of 2019 was $237,000, or $0.02 per diluted share, compared to a net loss of $266,000, or $0.03 per diluted share, for the same period last year.

As of September 30, 2019, the company reported $4.45 million in cash, cash equivalents and short-term bank deposits.

About Tikcro Technologies

Tikcro Technologies Ltd. TIKRF has developed certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro's website at www.tikcro.com.

Safe Harbor Statement

Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing or enter into strategic partnerships and the risks related to early stage biotechnology projects, including, but not limited to, obtaining required licenses at reasonable commercial terms, the development, testing, regulatory approval and commercialization of our proposed products, intellectual property rights, competition, exposure to lawsuits and dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Form 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods.  We undertake no duty to update any forward-looking information.

 

 

Tikcro Technologies Ltd.

Condensed Balance Sheets

(US dollars in thousands)





















September 30, 

2019

Unaudited



December 31,

2018

Audited





Assets













Current assets













Cash and cash equivalents

$

4,451



$

280







Short-term bank deposits



-





5,015







Receivables and other financial asset

107



52







     Total current assets

4,558



5,347





















Property and equipment, net

75



100







Operating lease right-of-use asset

26



-

























     Total assets

$

4,659



$

5,447



















Liabilities and Shareholders' Equity

















Current liabilities:













Other current liabilities

$

228



$

300







Operating lease – short term liability

36



-









264



300





















Shareholders' equity

4,395



5,147





















Total liabilities and shareholders' equity

$

4,659



$

5,447

























 

 

 

Tikcro Technologies Ltd.

Statements of Operations

(US dollars in thousands, except per share data)



















































Three Months Ended 

September 30,



Nine Months Ended 

   September  30,









2019



2018



2019



2018























Research and development

expenses

$

117

$

117

$

382

$

528























General and administrative

expenses, net



146



175



433



483























Total operating expenses



263



292



815



1,011























Operating loss



(263)



(292)



(815)



(1,011)

























Financial income, net



26



26



59



27

























Net loss

$

(237)

$

(266)

$

(756)

$

(984)























Basic and diluted net loss per share

$

(0.02)

$

(0.03)

$

(0.08)

$

(0.10)





















Weighted average number of shares

used computing basic and diluted

loss per share



9,879



9,879



9,879



9,879



 

 

Cision View original content:http://www.prnewswire.com/news-releases/tikcro-technologies-reports-third-quarter-2019-results-300962969.html

SOURCE Tikcro Technologies Ltd.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsSmall CapPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!